Hjem › Nyrekreft (nyrecellekarcinom) › Ohio
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Ohio
26 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i Ohio.
Byer i Ohio
- Cleveland14 studier
- Columbus13 studier
- Akron5 studier
- Cincinnati5 studier
- Dayton5 studier
- Toledo3 studier
- Parma3 studier
- Youngstown3 studier
Offisiell studietekst (engelsk)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Cleveland
- Research Site, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Cleveland Site, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07300241A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- og 44 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #10, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- Ohio State University Comprehensive Cancer Center, Columbus
- og 22 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT04981509DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04981119A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Local Institution - 0135, Cincinnati
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06863311Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Miami Valley Hospital South, Centerville
- og 13 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05327686ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Aultman Health Foundation, Canton
- og 10 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06661720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- University Hospitals Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05361720Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06966024Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Cincinnati
- Xencor Investigative Site, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05433142A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- James Cancer Hospital and Solove Research Institute, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT03972657KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Ohio State University, Columbus
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jun. 2026 · NCT06026410Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Cleveland Clinic, Cleveland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. mai 2026 · NCT05363280Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alle aldre · Alle kjønn · Oppdatert 9. mar. 2026 · NCT04792463Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Gabrail Cancer & Research Center, Canton
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. des. 2025 · NCT05856981A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2025 · NCT06805825A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- The Ohio State University, Columbus
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT06682793Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Indu and Raj Soin Medical Center, Beavercreek
- og 20 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04510597A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. nov. 2024 · NCT05824975Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.